A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients
Evaluating the Efficacy and safety of Adebrelimab in Combination with Platinum-based Doublet Chemotherapy and SHR-8068 as First-line Therapy for Patients with Advanced or Metastatic NSCLC Carrying STK11/KEAP1/KRAS Mutations
Non-squamous Non-small Cell Lung Cancer
DRUG: Adebrelimab + SHR-8068 + Pemetrexed + Carboplatin|DRUG: Camrelizumab + Pemetrexed + Carboplatin|DRUG: Adebrelimab + Pemetrexed + Carboplatin
Investigator-assessed Objective Response Rate (Phase One), about 3 years|Overall Survival (Phase Two), about 3.5 years
The incidence and severity of Adverse Events (AEs) (Phases One and Two), about 4.5 years|Duration of Response (DoR) based on Investigator Assessment (Phases One and Two), about 6.5 years|Disease Control Rate (DCR) based on Investigator Assessment (Phases One and Two), about 6.5 years|Progression-Free Survival (PFS) based on Investigator Assessment (Phases One and Two), about 6.5 years|Overall Survival (OS) (Phase One), about 3.5 years|Objective Response Rate (ORR) based on Investigator Assessment (Phase Two), about 4.5 years
Evaluating the Efficacy and safety of Adebrelimab in Combination with Platinum-based Doublet Chemotherapy and SHR-8068 as First-line Therapy for Patients with Advanced or Metastatic NSCLC Carrying STK11/KEAP1/KRAS Mutations